Anidulafungin-13C6

O[C@@H]1C[C@@H](C(N[C@H](C(N[C@H](C(N2[C@H](C(N[C@@H]([C@@H](C[C@@H](C(N[C@H](C3=O)[C@@H](C)O)=O)NC([13C]4=[13CH][13CH]=[13C]([13CH]=[13CH]4)C5=CC=C(C=C5)C6=CC=C(C=C6)OCCCCC)=O)O)O)=O)[C@H]([C@H](C2)C)O)=O)[C@H](O)C)=O)[C@@H]([C@H](C7=CC=C(C=C7)O)O)O)=O)N3C1

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Zhanel GG, et al. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species. Antimicrob Agents Chemother. 1997 Apr;41 (4) :863-5|[3]Locke JB, et al. Characterization of In Vitro Resistance Development to the Novel Echinocandin CD101 in Candida Species. Antimicrob Agents Chemother. 2016 Sep 23;60 (10) :6100-7.